{"schema_version":"1.0","type":"article","title":"聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒","url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.md","lang":"zh-Hant","date":"2026-07-20","publish_at":"2026-07-20T08:58:00+08:00","updated_at":"2026-07-20","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","MASH","Madrigal Pharmaceuticals","Rezdiffra","resmetirom","siRNA","Ribo Life Science","Ribocure","Arrowhead Pharmaceuticals","ARO-PNPLA3","PNPLA3","THR-beta","FGF21","GLP-1","BD 授權","台灣生技"],"summary":"Rezdiffra 已把 MASH 市場與商業化基礎設施打開；Madrigal 再以 Ribo 六條 siRNA 管線與 Arrowhead ARO-PNPLA3，建立基石藥加精準聯用矩陣。","key_points":[],"facts":[],"sections":["01｜Rezdiffra 很成功，但它不是 MASH 的終點","02｜為什麼 Madrigal 看上 siRNA？","03｜Ribo Life Science 與 Ribocure：Madrigal 為什麼一次買六條 siRNA？","04｜Madrigal 不只找 Ribo，也找 Arrowhead：siRNA 已成為第二成長曲線","05｜Madrigal 的最大資產，其實是 MASH 商業化基礎設施","06｜台灣對 MASH 與肝病仍有幾個觀察點","結語｜MASH 不是單藥戰爭，而是基石藥與聯用矩陣的戰爭","參考資料"],"references":[{"title":"[Facebook","source":"藥時事原始貼文，2026-07-20]","date":"","url":"https://www.facebook.com/61568446257142/posts/1371920785993874/"},{"title":"[FDA","source":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease，2024-03-14]","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease"},{"title":"[New England Journal of Medicine","source":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis，2024]","date":"","url":"https://www.nejm.org/doi/10.1056/NEJMoa2309000"},{"title":"[Madrigal","source":"2025 Full-Year Financial Results，2026-02-19]","date":"","url":"https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0"},{"title":"[Madrigal","source":"2026 First-Quarter Financial Results，2026-05-06]","date":"","url":"https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-first-quarter-2026-financial"},{"title":"[Novo Nordisk","source":"Wegovy Receives FDA Accelerated Approval for MASH，2025-08-15]","date":"","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916416"},{"title":"[Roche","source":"Agreement to Acquire 89bio and Pegozafermin，2025-09-18]","date":"","url":"https://www.roche.com/media/releases/med-cor-2025-09-18"},{"title":"[Madrigal","source":"Exclusive Global License for Six Ribo siRNA Programs，2026-02-11]","date":"","url":"https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-licensing"},{"title":"[Ribocure","source":"Ribo and Madrigal Reach First Major MASH siRNA Milestone，2026-07-02]","date":"","url":"https://ribocure.com/news/"},{"title":"[Madrigal","source":"Global License for Arrowhead ARO-PNPLA3，2026-05-05]","date":"","url":"https://ir.madrigalpharma.com/node/17406"},{"title":"[景凱生技","source":"Company History and Liver-Disease Pipeline]","date":"","url":"https://www.taiwanj.com/pages/page_history_en"},{"title":"[欣耀生醫","source":"SNP-630 MASH Program]","date":"","url":"https://www.sinewpharma.com/en/products-detail2-4.htm"}],"images":[{"alt":"Rezdiffra 從 FDA 加速核准走向 MASH 基石藥；確認性研究仍在進行","url":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/figure-01.webp"},{"alt":"MASH 治療矩陣由 Rezdiffra、GLP-1、FGF21 與 siRNA 四種互補機制構成","url":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/figure-02.webp"},{"alt":"Madrigal 以 Ribo 六條早期 siRNA 管線與 Arrowhead 臨床階段 ARO-PNPLA3 建立雙軌策略","url":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/figure-03.webp"},{"alt":"Rezdiffra 的臨床、診斷、給付與處方網絡，成為後續 MASH 聯用管線的商業放大器","url":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/figure-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-20）。聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒。https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-20-madrigal-mash-sirna-platform-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}